NexImmune (OTCMKTS:NEXI – Get Free Report) is projected to announce its resultson Tuesday, November 17th. Analysts expect NexImmune to announce earnings of ($13.25) per share for the quarter.
NexImmune Stock Performance
NexImmune has a 1 year low of $0.00 and a 1 year high of $2.17.
NexImmune Company Profile
NexImmune, Inc was a biotechnology company focused on developing cell-based immunotherapies for cancer. Its Artificial Immune Modulation (AIM) platform was designed to activate and expand T cells that recognize specific cancer-associated targets.
The company’s investigational programs included NEXI-001, a T-cell therapy for acute myeloid leukemia, and NEXI-002, a program for multiple myeloma. NexImmune was based in Gaithersburg, Maryland, and its therapies were in clinical development rather than commercially available.
NexImmune later discontinued operations and filed for Chapter 7 bankruptcy in 2023.
See Also
- Five stocks we like better than NexImmune
- Wall Street May Be Making a Big Mistake With monday.com Stock
- Are These 2 Mid-Cap Growth Stocks Worth the Risk?
- Oklo Changes the Narrative: Does a Nuclear Stock Price Explosion Come Next?
- Cloudflare’s 20% Sell-Off May Have Created an Opening for Investors
Receive News & Ratings for NexImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexImmune and related companies with MarketBeat.com's FREE daily email newsletter.
